Table 1.
Pathological lymph node status after NAST according to clinical nodal status after NAST and biological subtype.
| Biological Subtype | ypN0 N (%) |
ypN+ N (%) |
p-Value a | |
|---|---|---|---|---|
| ycN0 | luminal HER2- (N = 58) | 15 (25.9) | 43 (74.1) | <0.001 |
| TNBC (N = 36) | 27 (75.0) | 9 (25.0) | ||
| HER2+ (N = 38) | 31 (81.6) | 7 (18.4) | ||
| Overall (N = 132) | 73 (55.3) | 59 (44.7) | ||
| ycN+ | luminal HER2- (N = 35) | 14 (40.0) | 21 (60.0) | 0.010 |
| TNBC (N = 21) | 13 (61.9) | 8 (38.1) | ||
| HER2+ (N = 21) | 17 (81.0) | 4 (19.0) | ||
| Overall (N = 77) | 44 (57.1) | 33 (42.9) | ||
| ycNx * | luminal HER2- (N = 17) | 6 (35.3) | 11 (64.7) | 0.080 |
| TNBC (N = 6) | 3 (50.0) | 3 (50.0) | ||
| HER2+ (N = 10) | 8 (80.0) | 2 (20.0) | ||
| Overall (N = 33) | 17 (51.5) | 16 (48.5) |
Abbreviations: TNBC, triple-negative breast cancer; NAST, neoadjuvant systemic treatment; a comparing ypN0 rate between subtypes; * missing data.